U.S. Markets closed

Biogen first-quarter profit rises 20 percent

April 24 (Reuters) - Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday on higher sales of its muscle disease treatment Spinraza.

Net income attributable to the company rose to $1.41 billion, or $7.15 per share, in the quarter ended March 31, from $1.17 billion, or $5.54 per share, a year earlier.

Total revenue rose to $3.49 billion from $3.13 billion. (Reporting by Manojna Maddipatla and Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta)